Vortioxetine's post-marketing safety profile determined through cluster analysis of global adverse event reports

被引：0
|
作者：
Ekhart, Corine [1 ]
van Hunsel, Florence [1 ]
van Puijenbroek, Eugene [1 ,2 ]
Chandler, Rebecca [3 ]
Meldau, Eva-Lisa [3 ]
Noren, Niklas [3 ]
机构：
[1] Netherlands Pharmacovigilance Ctr Lareb, Shertogenbosch, Netherlands
[2] Univ Groningen, Groningen, Netherlands
[3] Uppsala Monitoring Ctr, Uppsala, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4070
引用
收藏
页码：497 / 497
页数：1
相关论文
共 50 条
  • [41] Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting system
    Fan, Ziyi
    Xu, Yanan
    Guo, Shuding
    Song, Bin
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [42] Post-Marketing Safety of Temozolomide: A Pharmacovigilance Study Based on the Food and Drug Administration Adverse Event Reporting System
    Lin, Yuhao
    Deng, Muling
    Xu, Siqi
    Chen, Chuanben
    Ding, Jianming
    ONCOLOGY, 2025,
  • [43] Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
    Xing, Xiaoxuan
    Zhang, Xiaotong
    Wang, Ke
    Wang, Zhizhou
    Feng, Yingnan
    Li, Xiaoxi
    Hua, Yiming
    Zhang, Lan
    Dong, Xianzhe
    ALZHEIMERS RESEARCH & THERAPY, 2025, 17 (01)
  • [44] Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
    Li, Huqun
    Wang, Chongshu
    Guo, Cuilian
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] Safety of remdesivir in COVID-19 patients: post-marketing evaluation on spontaneous adverse event reporting system
    Cesaro, M.
    Rafaniello, C.
    Di Mauro, C.
    Zinzi, A.
    Ferrajolo, C.
    Scavone, C.
    Sportiello, L.
    Sullo, M.
    Rossi, F.
    Capuano, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S116 - S117
  • [46] Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Liu, Yan-xin
    Dong, Chang-jiang
    He, Xu-cheng
    Shu, Ya-min
    Wu, Pan
    Zou, Jian
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2022, 25 : 377 - 390
  • [47] Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system
    Zhang, Yi
    Jia, Xiaocan
    Shi, Xuezhong
    Chen, Yongyue
    Xue, Mingyi
    Shen, Guibin
    Wen, Long
    Qiao, Ying
    Yang, Yongli
    GENERAL HOSPITAL PSYCHIATRY, 2024, 90 : 22 - 29
  • [48] Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Christiane Michel
    Emil Scosyrev
    Michael Petrin
    Robert Schmouder
    Clinical Drug Investigation, 2017, 37 : 415 - 422
  • [49] Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel, Christiane
    Scosyrev, Emil
    Petrin, Michael
    Schmouder, Robert
    CLINICAL DRUG INVESTIGATION, 2017, 37 (05) : 415 - 422
  • [50] Post-Marketing Safety of Anti-Calcitonin Gene Related Peptide Antibodies: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Giunchi, V.
    Fusaroli, M.
    Antonazzo, I. C.
    Hyeraci, G.
    Raschi, E.
    Poluzzi, E.
    Mazzaglia, G.
    Roberto, G.
    DRUG SAFETY, 2022, 45 (10) : 1245 - 1245
12345